Ginsenoside Rg1 ameliorates cardiac oxidative stress and inflammation in streptozotocin-induced diabetic rats. 2019

Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
Emergency Department, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, People's Republic of China.

Background and purpose: Ginsenoside Rg1 (GS Rg1), as an important active substance of Panax ginseng, has been proven to have elaborate cardioprotective effects. The purpose of this study was to detect that GS Rg1 attenuates cardiac oxidative stress and inflammation in streptozotocin (STZ)-induced diabetic rats (DM). Methods: Cardiac function was assessed by heart rate and blood pressure. Markers relevant to myocardial oxidative stress and antioxidant capacity, and inflammatory reaction factors were detected. The mRNA and protein expression were detected by RT-qPCR and Western blot, respectively. Results: GS Rg1 treatment significantly reduced the symptoms of cardiac hypertrophy and hypertension, and also decreased oxidative stress, inflammation response, NF-κB expression and NLRP3 inflammasome expression. GS Rg1 enhanced mitochondrial biogenesis by increasing PGC-1α, complex III and complex Ⅳ expression. GS Rg1 treatment significantly increased the expression of AMPK, Nrf2 and HO-1 in cardiac tissues. Conclusion: GS Rg1 exhibited protective effect against STZ-induced cardiac dysfunction, which is potentially associated with AMPK/Nrf2/HO-1 signal pathway.

UI MeSH Term Description Entries

Related Publications

Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
May 2015, Journal of Zhejiang University. Science. B,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
October 2015, Molecular and cellular biochemistry,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
December 2022, Pharmaceutical biology,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
January 2023, BMC complementary medicine and therapies,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
April 2021, Chemico-biological interactions,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
December 2013, Naunyn-Schmiedeberg's archives of pharmacology,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
April 2016, Journal of cellular and molecular medicine,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
November 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
October 2021, Cells,
Qiaoji Qin, and Nan Lin, and Huan Huang, and Xuezhi Zhang, and Xuelei Cao, and Yongbin Wang, and Peng Li
January 2020, Oxidative medicine and cellular longevity,
Copied contents to your clipboard!